Author

Seul Gi Lee 1

1 Celltrion,Incheon,Korea (Republic of)

A Large Pooled Safety Analysis of 3 Post-Marketing Studies Conducted in Inflammatory Bowel Disease Patients Treated with Biosimilar Infliximab (CT-P13)

Sang Joon Lee, KyungMin Baek, Yoon Jee Lee, Sujin Lee, Houng Kim, Seul Gi Lee, Jeong Eun Park

EARLY INFLIXIMAB TROUGH LEVELS PREDICT LATE EFFICACY OF INFLIXIMAB IN A RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH ACTIVE CROHN'S DISEASE COMPARING CT-P13 AND INNOVATOR INFLIXIMAB

Jae Hee Cheon, Kang-Moon Lee, Young-Ho Kim, Byong Duk Ye, Changsoo Eun, Sung Young Lee, Seul Gi Lee, Joon Ho Lee, Houng Kim, Pamela Selema, Raymond Cheung, Stefan Schreiber

EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL

Walter Reinisch, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw KierkuĊ›, Maciej Kowalski, Shomron Ben-Horin, Stefan Schreiber, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Yun Ah Kim, Se Ra Kim, Seul Gi Lee, Byong Duk Ye

Item 1 - 3 / 3
1